Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to treat hyperglycemia in patients with type 2 diabetes mellitus. Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%).
- Mechanism
- Curator reviewed
Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying.
- Primary indication
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Curator reviewed · 3 structured indications
- Formula / weight
- C18H21N5O2 · 339.3916 g/mol (avg)
- First approval
- Canada, 2013 · United States, 2013 · European Union, 2016
- Brand names
Resolves to
ZSBOMTDTBDDKMP-OAHLLOKOSA-NSMILESCN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Alogliptin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account